高级检索
当前位置: 首页 > 详情页

Qigesan inhibits esophageal cancer cell invasion and migration by inhibiting Gas6/Axl-induced epithelial-mesenchymal transition

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Coll Integrated Chinese & Western Med, Shijiazhuang 050017, Hebei, Peoples R China [2]Tangshan Maternal & Children Hosp, Dept Clin Lab, Tangshan 063000, Hebei, Peoples R China [3]Hebei Med Univ, Res Ctr, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China [4]Hebei Med Univ, Tumor Hosp Hebei Prov, Dept Tradit Chinese Med, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China
出处:
ISSN:

关键词: TCM formulas ESCC Gas6/Axl epithelial-mesenchymal transition cancer metastasis

摘要:
Qigesan (QGS) has been used to effectively treat esophageal cancer (EC) for decades in China, but the mechanism by which it suppresses EC metastasis remains unknown. In this study, we examined the effects of QGS on EC cell mobility. Using immunohistochemistry and immunofluorescence, expression of Gas6 and Axl, which promote tumor cell migration and invasion, was examined in carcinoma tissues and adjacent normal tissues from EC patients. Levels of Gas6, Axl, and the Gas6/Axl complex were also examined in ECA109 and TE13 EC cells treated with QGS. In addition, immunofluorescent staining and quantitative protein analysis were used to examine E-cadherin, N-cadherin, and Snail levels in ECA109 and TE13 EC cells after QSG administration, and cell mobility was assessed. The results demonstrated that levels of Gas6 and Axl expression are higher in EC tissues than in adjacent normal tissues. Moreover, QGS decreased Gas6/Axl levels, increased E-cadherin expression, decreased Snail and N-cadherin expression, and inhibited epithelial-mesenchymal transition (EMT) in EC cells. QGS thus suppresses EMT in EC by inhibiting Gas6/Axl binding.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 1 区 老年医学 3 区 细胞生物学
最新[2025]版:
JCR分区:
出版当年[2020]版:
Q1 GERIATRICS & GERONTOLOGY Q2 CELL BIOLOGY
最新[2024]版:

影响因子: 最新[2024版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Coll Integrated Chinese & Western Med, Shijiazhuang 050017, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Hebei Med Univ, Coll Integrated Chinese & Western Med, Shijiazhuang 050017, Hebei, Peoples R China [4]Hebei Med Univ, Tumor Hosp Hebei Prov, Dept Tradit Chinese Med, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号